Výsledky vyhledávání - "Veronique R. De Jager"

Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832

Autor: Rodney Dawson, Andreas H. Diacon, Kim Narunsky, Veronique R. De Jager, Kelly W. Stinson, Xiaoyan Zhang, Yongge Liu, Jeffrey Hafkin

Publikováno v: Antimicrobial Agents and Chemotherapy.

OPC-167832, an inhibitor of decaprenylphosphoryl-β- d -ribose 2’-oxidase, demonstrated potent antituberculosis activity and a favorable safety profile in preclinical studies. This report describes the first two clinical studies of OPC-167832: (i)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c7ff8a85bf2374ae82d1003e8b21421
https://doi.org/10.1128/aac.01477-22

Zobrazit plný text záznamu

Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis

Publikováno v: Science translational medicine. 13(579)

Early bactericidal activity studies monitor daily sputum bacterial counts in individuals with tuberculosis (TB) for 14 days during experimental drug treatment. The rate of change in sputum bacterial load over time provides an informative, but imperfe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b698b3728e2283b8b224a9da3b9471b0
https://pubmed.ncbi.nlm.nih.gov/33536283

Zobrazit plný text záznamu

Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial

Autor: Sachiko Miyahara, Evelyn Hogg, Michael E. Urbanowski, Rodney Dawson, Andreas H. Diacon, Xin Sun, William R. Bishai, Richard Hafner, Veronique R. de Jager, Courtney V. Fletcher, Kathleen Donahue, Susan Swindells

Publikováno v: The Lancet Microbe, Vol 1, Iss 2, Pp e84-e92 (2020)
Lancet Microbe

Summary Background Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial 2 days of tuberculosis treatment, but that the activity of isoniazid declines substantially after day 3 of treatment. In this 14-day, ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16df6c08c941cc3901ba7f36195fb3f3
http://www.sciencedirect.com/science/article/pii/S2666524720300112

Zobrazit plný text záznamu

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis

Autor: Divan Aristo Burger, Rodney Dawson, Mendel Carl M, Veronique R. de Jager, Kim Narunsky, Frances Pappas, Naadira Vanker, Jerry R Nedelman, Daniel Everitt, Andreas H. Diacon

Publikováno v: Antimicrobial Agents and Chemotherapy

Linezolid is increasingly used for the treatment of tuberculosis resistant to first-line agents, but the most effective dosing strategy is yet unknown. From November 2014 to November 2016, we randomized 114 drug-sensitive treatment-naive pulmonary tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7c1d5a3618f440f8c25a47d1f50cefd
http://europepmc.org/articles/PMC7179319

Zobrazit plný text záznamu

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children

Autor: Rene Kitshoff, Betsy Smith, Jeannine du Bois, Andreas H. Diacon, Jennifer Norman, Anneke C. Hesseling, Elin M. Svensson, Sharon Nachman, Lubbe Wiesner, Veronique R. de Jager, Anthony J. Garcia-Prats

Publikováno v: British Journal of Clinical Pharmacology. 84:2384-2392

Aims Bedaquiline is an important novel drug for treatment of multidrug-resistant tuberculosis, but no paediatric formulation is yet available. This work aimed to explore the possibility of using the existing tablet formulation in children by evaluati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88ef61afbf380c18967bd99e721c6f38
https://doi.org/10.1111/bcp.13696

Zobrazit plný text záznamu

Telacebec (Q203), a New Antituberculosis Agent

Autor: Rodney Dawson, Jeongjun Kim, Veronique R. de Jager, Jinho Choi, Jane Hutchings, Kiyean Nam, Naadira Vanker, Christo van Niekerk, Andreas H. Diacon, Lize van der Merwe

Publikováno v: New England Journal of Medicine. 382:1280-1281

Telacebec (Q203), a New Antituberculosis Agent Telacebec (Q203) is a novel drug that targets Mycobacterium tuberculosis cellular energy production through inhibition of the mycobacterial cytochrome...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b85c18a8356f83611d172fde5e03833
https://doi.org/10.1056/nejmc1913327

Zobrazit plný text záznamu

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1 rifampicin

Autor: Norbert Heinrich, Elin M. Svensson, Rodney Dawson, Stephen H. Gillespie, Michael Hoelscher, Martin J. Boeree, Andreas H. Diacon, Kim Narunsky, Naadira Vanker, Rob E. Aarnoutse, Lindsey H.M. te Brake, Veronique R. de Jager, Patrick P. J. Phillips

Publikováno v: European Respiratory Journal, 58
European Respiratory Journal, 58, 1

BackgroundAccumulating data indicate that higher rifampicin doses are more effective and shorten tuberculosis (TB) treatment duration. This study evaluated the safety, tolerability, pharmacokinetics, and 7- and 14-day early bactericidal activity (EBA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70ac5eb422b3d507ce393739caf79d94
https://doi.org/10.1183/13993003.00955-2020

Zobrazit plný text záznamu

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children

Autor: Elin M, Svensson, Jeannine, du Bois, Rene, Kitshoff, Veronique R, de Jager, Lubbe, Wiesner, Jennifer, Norman, Sharon, Nachman, Betsy, Smith, Andreas H, Diacon, Anneke C, Hesseling, Anthony J, Garcia-Prats

Publikováno v: British journal of clinical pharmacology.

Bedaquiline is an important novel drug for treatment of multidrug-resistant tuberculosis, but no paediatric formulation is yet available. This work aimed to explore the possibility of using the existing tablet formulation in children by evaluating th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ae2dc21df21c320b3b1d10b58f6516f8
https://pubmed.ncbi.nlm.nih.gov/29952141

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání